Liftstream is an executive search recruitment company in the life sciences sector
Mr Jorn Aldag – UniQure – Executive Leadership Series
Authored by James Sheppard
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Aegerion, Alexion, Amgen, BioMarin, Bloomberg, Breakthrough Therapy, Catalyst Pharmaceutical Partners, Chiesi, Chiesi Farmaceutici, EMA, FDA, Flemming Ornskov, Human Genetic Therapies, Jean-Jacques Bienaimé, Kamada, Kyprolis, life sciences, lysosomal storage diseases, M&A, Nexavar, NPS Pharmaceuticals, Onyx, Orphan drugs, pharmaceutical industry, rare diseases, regenerative medicine, Roche, San Francisco, Sarepta, Shire, speciality pharma, Ugo di Francesco, uniQure, Zymenex
Leave a comment
Audentes Therapeutics raises $30 in series A financing
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged 5AM Ventures, Audentes Therapeutics, Bluebird bio, Chiesi, Gene therapy, Glybera, Jonathan Silverstein, Kush Parmar, Matthew R. Patterson, OrbiMed Advisors, Orphan drugs, Pompe Disease, rare diseases, series A funding, Thomas J. Schuetz, Thomas Woiwode, uniQure, venture capital, Versant Ventures, x-linked myotubular myopathy, XLMTM
Leave a comment
Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events:
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Actelion, Alexion, BioMarin, BlubirdBio, Chiesi, Elelyso, Emil Kakkis, Enobia, Forbes, Genzyme, IPO, Lysogene, M&A, Prosensa, Protalix, rare diseases, regulatory affairs, regulatory approval, Replagal, Sanofi, Shire, Soliris, Supernus Pharmaceuticals, ultra-rare diseases, Ultragenyx, uniQure, VPRIV
Leave a comment